Insulet Corporation announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott's FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This makes Omnipod 5 the most connected tubeless AID system in the U.S. The Omnipod 5 System simplifies diabetes management and has shown to improve results by eliminating the need for multiple daily injections (MDI) therapy and automatically adjusting insulin delivery every five minutes using its advanced SmartAdjustTM technology. As the number one prescribed and number one favorite pump1 in the U.S., the waterproof2, discreet, and wearable Omnipod 5 is the first tubeless AID system that communicates with a CGM, proactively correcting for highs and helping to protect against lows, day and night. Omnipod 5 user John Rowley, who lives in the United Kingdom where the FreeStyle Libre 2 Plus sensor integration launched earlier this year, had been using MDI for 36 years before making the switch to Pod therapy.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
275.81 USD | +1.08% | +1.46% | +5.65% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
275.81USD | +1.08% | +1.46% | 19.35B | ||
113.48USD | -0.38% | +1.04% | 197B | ||
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PODD Stock
- News Insulet Corporation
- Insulet Corporation Announces Omnipod® 5 System Now Compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the U.S